
Colorado Therapeutics develops xenogenic tissue matrix products for soft tissue reinforcement and regeneration.
Founded in Broomfield, Colorado, Colorado Therapeutics specializes in developing xenogenic tissue matrix products aimed at soft tissue reinforcement and regeneration. The company's core mission is to advance medical technology through innovative biologic implants that enhance tissue repair and regenerative processes. Their flagship product, XI-S+™, is a lightweight biologic implant designed for a variety of soft tissue and vascular applications, targeting both the medical and surgical markets.
Notable affiliations include a license agreement with Micro Interventional Devices for the use of PolyCor™ Anchoring Technology. Colorado Therapeutics has achieved significant milestones in research and development, positioning itself as a leader in the biologic implant sector. The company's impact is marked by its contributions to improving patient outcomes in soft tissue repair and regenerative medicine.

TissueForm
tissueforminc.com

Snoasis Medical
snoasismedical.com

Exogenesis

Pegasus Biologics
pegasusbio.com

NeXtGen Biologics

Histogen
histogen.com

ECM Therapeutics

Xylos
xyloscorp.com

NovoThelium
novothelium.com

RegeneRx Biopharmaceuticals

Circle Biologics

Endogena Therapeutics
RegenX

EndoCellutions
endocellutions.com

X-Cor Therapeutics
Companies similar to Colorado Therapeutics include TissueForm, Snoasis Medical, Exogenesis and Pegasus Biologics.
Colorado Therapeutics was founded in 2015.
Colorado Therapeutics' headquarters is located in Louisville, CO, US.
Colorado Therapeutics' most recent funding round was for $2.6M (USD) in April 2017.
As of Apr 17, 2017, Colorado Therapeutics has raised a total of $6.9M (USD).
Colorado Therapeutics has 30 employees as of Feb 5, 2024.